PT1948816E - Processos melhorados de focalização - Google Patents

Processos melhorados de focalização Download PDF

Info

Publication number: PT1948816E
Authority: PT; Portugal
Prior art keywords: dna; amplicons; beads; homo sapiens; pcr
Prior art date: 2005-10-24

Application number

PT06817236T

Other languages

English (en)

Portuguese (pt)

Original Assignee

Univ Johns Hopkins

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-24

Filing date

2006-10-20

Publication date

2012-03-19

2006-10-20 Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins

2012-03-19 Publication of PT1948816E publication Critical patent/PT1948816E/pt

Links

238000000034 method Methods 0.000 title claims abstract description 45
108010014303 DNA-directed DNA polymerase Proteins 0.000 claims abstract description 18
102000016928 DNA-directed DNA polymerase Human genes 0.000 claims abstract description 18
108020004414 DNA Proteins 0.000 claims description 278
239000011324 bead Substances 0.000 claims description 143
238000003199 nucleic acid amplification method Methods 0.000 claims description 61
230000003321 amplification Effects 0.000 claims description 60
239000000523 sample Substances 0.000 claims description 40
108091093088 Amplicon Proteins 0.000 claims description 33
238000004458 analytical method Methods 0.000 claims description 17
230000008569 process Effects 0.000 claims description 16
239000011159 matrix material Substances 0.000 claims description 14
239000004530 micro-emulsion Substances 0.000 claims description 14
238000009396 hybridization Methods 0.000 claims description 12
239000002773 nucleotide Substances 0.000 claims description 7
125000003729 nucleotide group Chemical group 0.000 claims description 7
239000003999 initiator Substances 0.000 claims description 6
239000012491 analyte Substances 0.000 claims description 5
239000003153 chemical reaction reagent Substances 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 5
238000012360 testing method Methods 0.000 claims description 5
238000005096 rolling process Methods 0.000 claims description 3
239000003471 mutagenic agent Substances 0.000 claims description 2
231100000707 mutagenic chemical Toxicity 0.000 claims description 2
238000004925 denaturation Methods 0.000 claims 1
230000036425 denaturation Effects 0.000 claims 1
238000013467 fragmentation Methods 0.000 claims 1
238000006062 fragmentation reaction Methods 0.000 claims 1
230000003505 mutagenic effect Effects 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 abstract description 98
230000035772 mutation Effects 0.000 abstract description 61
201000011510 cancer Diseases 0.000 abstract description 32
238000001514 detection method Methods 0.000 abstract description 17
230000035945 sensitivity Effects 0.000 abstract description 17
230000006872 improvement Effects 0.000 abstract description 6
241000282414 Homo sapiens Species 0.000 description 134
238000003752 polymerase chain reaction Methods 0.000 description 100
239000012634 fragment Substances 0.000 description 98
210000002381 plasma Anatomy 0.000 description 64
239000000839 emulsion Substances 0.000 description 34
239000000047 product Substances 0.000 description 31
238000003556 assay Methods 0.000 description 30
238000006243 chemical reaction Methods 0.000 description 30
101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 28
102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 28
102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 24
239000011049 pearl Substances 0.000 description 19
238000000684 flow cytometry Methods 0.000 description 18
238000012163 sequencing technique Methods 0.000 description 18
239000000203 mixture Substances 0.000 description 17
108700001666 APC Genes Proteins 0.000 description 15
208000003200 Adenoma Diseases 0.000 description 15
230000008685 targeting Effects 0.000 description 15
102100030708 GTPase KRas Human genes 0.000 description 13
101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 13
238000013459 approach Methods 0.000 description 13
239000000872 buffer Substances 0.000 description 13
210000001072 colon Anatomy 0.000 description 13
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 12
238000011002 quantification Methods 0.000 description 12
210000004027 cell Anatomy 0.000 description 11
239000003550 marker Substances 0.000 description 11
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 10
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 10
208000001333 Colorectal Neoplasms Diseases 0.000 description 10
210000005170 neoplastic cell Anatomy 0.000 description 10
108091028043 Nucleic acid sequence Proteins 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
101150080074 TP53 gene Proteins 0.000 description 9
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
108091034117 Oligonucleotide Proteins 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
239000008280 blood Substances 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
206010001233 Adenoma benign Diseases 0.000 description 7
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 7
238000007847 digital PCR Methods 0.000 description 7
230000003902 lesion Effects 0.000 description 7
230000036438 mutation frequency Effects 0.000 description 7
108020004707 nucleic acids Proteins 0.000 description 7
102000039446 nucleic acids Human genes 0.000 description 7
150000007523 nucleic acids Chemical class 0.000 description 7
210000001599 sigmoid colon Anatomy 0.000 description 7
239000011534 wash buffer Substances 0.000 description 7
108010006785 Taq Polymerase Proteins 0.000 description 6
229960002685 biotin Drugs 0.000 description 6
239000011616 biotin Substances 0.000 description 6
239000012071 phase Substances 0.000 description 6
229910052697 platinum Inorganic materials 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
108020004705 Codon Proteins 0.000 description 5
102000053602 DNA Human genes 0.000 description 5
235000020958 biotin Nutrition 0.000 description 5
230000000295 complement effect Effects 0.000 description 5
239000005546 dideoxynucleotide Substances 0.000 description 5
210000002540 macrophage Anatomy 0.000 description 5
238000003753 real-time PCR Methods 0.000 description 5
206010009944 Colon cancer Diseases 0.000 description 4
238000001712 DNA sequencing Methods 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
206010028851 Necrosis Diseases 0.000 description 4
108010090804 Streptavidin Proteins 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
210000001815 ascending colon Anatomy 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
238000002052 colonoscopy Methods 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
230000002550 fecal effect Effects 0.000 description 4
210000003608 fece Anatomy 0.000 description 4
239000000463 material Substances 0.000 description 4
230000000869 mutational effect Effects 0.000 description 4
230000017074 necrotic cell death Effects 0.000 description 4
230000001338 necrotic effect Effects 0.000 description 4
238000011160 research Methods 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
102220066931 rs121913332 Human genes 0.000 description 4
238000012216 screening Methods 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
108010063905 Ampligase Proteins 0.000 description 3
201000009030 Carcinoma Diseases 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
101000958664 Homo sapiens Nucleus accumbens-associated protein 1 Proteins 0.000 description 3
101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 description 3
ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 3
102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 description 3
108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 3
230000001174 ascending effect Effects 0.000 description 3
230000027455 binding Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
230000008859 change Effects 0.000 description 3
238000010367 cloning Methods 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
238000011049 filling Methods 0.000 description 3
238000011901 isothermal amplification Methods 0.000 description 3
101150066555 lacZ gene Proteins 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
230000001394 metastastic effect Effects 0.000 description 3
206010061289 metastatic neoplasm Diseases 0.000 description 3
239000002480 mineral oil Substances 0.000 description 3
235000010446 mineral oil Nutrition 0.000 description 3
239000003921 oil Substances 0.000 description 3
239000011535 reaction buffer Substances 0.000 description 3
201000003780 rectum adenoma Diseases 0.000 description 3
230000010076 replication Effects 0.000 description 3
101150098466 rpsL gene Proteins 0.000 description 3
102200085789 rs121913279 Human genes 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
239000001226 triphosphate Substances 0.000 description 3
235000011178 triphosphate Nutrition 0.000 description 3
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
IMWZZHHPURKASS-UHFFFAOYSA-N Metaxalone Chemical compound CC1=CC(C)=CC(OCC2OC(=O)NC2)=C1 IMWZZHHPURKASS-UHFFFAOYSA-N 0.000 description 2
241000205160 Pyrococcus Species 0.000 description 2
108020004682 Single-Stranded DNA Proteins 0.000 description 2
201000008754 Tenosynovial giant cell tumor Diseases 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
ARLKCWCREKRROD-POYBYMJQSA-N [[(2s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 ARLKCWCREKRROD-POYBYMJQSA-N 0.000 description 2
230000006978 adaptation Effects 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 2
238000004166 bioassay Methods 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
208000035647 diffuse type tenosynovial giant cell tumor Diseases 0.000 description 2
238000009826 distribution Methods 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
239000013642 negative control Substances 0.000 description 2
230000009826 neoplastic cell growth Effects 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
241000894007 species Species 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
208000002918 testicular germ cell tumor Diseases 0.000 description 2
239000007762 w/o emulsion Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 description 1
VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
206010048832 Colon adenoma Diseases 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
238000007400 DNA extraction Methods 0.000 description 1
230000009946 DNA mutation Effects 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
241000167880 Hirundinidae Species 0.000 description 1
101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
206010027457 Metastases to liver Diseases 0.000 description 1
102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
108010010677 Phosphodiesterase I Proteins 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
101150063858 Pik3ca gene Proteins 0.000 description 1
241000288906 Primates Species 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 description 1
238000009098 adjuvant therapy Methods 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000010310 bacterial transformation Effects 0.000 description 1
239000012148 binding buffer Substances 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
238000009534 blood test Methods 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000008094 contradictory effect Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
URGJWIFLBWJRMF-JGVFFNPUSA-N ddTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 URGJWIFLBWJRMF-JGVFFNPUSA-N 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
210000001731 descending colon Anatomy 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000004744 fabric Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012997 ficoll-paque Substances 0.000 description 1
238000012921 fluorescence analysis Methods 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
230000007614 genetic variation Effects 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000009545 invasion Effects 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
238000007885 magnetic separation Methods 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
238000005457 optimization Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000009595 pap smear Methods 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
238000001558 permutation test Methods 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
238000007842 plasma-based assay Methods 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
230000010287 polarization Effects 0.000 description 1
239000013641 positive control Substances 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000012207 quantitative assay Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000012552 review Methods 0.000 description 1
102220000338 rs121913327 Human genes 0.000 description 1
102200006539 rs121913529 Human genes 0.000 description 1
102220277840 rs1554085480 Human genes 0.000 description 1
102220045959 rs587782518 Human genes 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
238000011896 sensitive detection Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
238000003860 storage Methods 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
210000001138 tear Anatomy 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
231100000588 tumorigenic Toxicity 0.000 description 1
230000000381 tumorigenic effect Effects 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
239000013598 vector Substances 0.000 description 1
238000003260 vortexing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R31/00—Arrangements for testing electric properties; Arrangements for locating electric faults; Arrangements for electrical testing characterised by what is being tested not provided for elsewhere
- G01R31/327—Testing of circuit interrupters, switches or circuit-breakers
- G01R31/3277—Testing of circuit interrupters, switches or circuit-breakers of low voltage devices, e.g. domestic or industrial devices, such as motor protections, relays, rotation switches
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R31/00—Arrangements for testing electric properties; Arrangements for locating electric faults; Arrangements for electrical testing characterised by what is being tested not provided for elsewhere
- G01R31/50—Testing of electric apparatus, lines, cables or components for short-circuits, continuity, leakage current or incorrect line connections
- G01R31/52—Testing for short-circuits, leakage current or ground faults
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02H—EMERGENCY PROTECTIVE CIRCUIT ARRANGEMENTS
- H02H1/00—Details of emergency protective circuit arrangements
- H02H1/0007—Details of emergency protective circuit arrangements concerning the detecting means
- H02H1/0015—Using arc detectors
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02H—EMERGENCY PROTECTIVE CIRCUIT ARRANGEMENTS
- H02H3/00—Emergency protective circuit arrangements for automatic disconnection directly responsive to an undesired change from normal electric working condition with or without subsequent reconnection ; integrated protection
- H02H3/26—Emergency protective circuit arrangements for automatic disconnection directly responsive to an undesired change from normal electric working condition with or without subsequent reconnection ; integrated protection responsive to difference between voltages or between currents; responsive to phase angle between voltages or between currents
- H02H3/32—Emergency protective circuit arrangements for automatic disconnection directly responsive to an undesired change from normal electric working condition with or without subsequent reconnection ; integrated protection responsive to difference between voltages or between currents; responsive to phase angle between voltages or between currents involving comparison of the voltage or current values at corresponding points in different conductors of a single system, e.g. of currents in go and return conductors
- H02H3/33—Emergency protective circuit arrangements for automatic disconnection directly responsive to an undesired change from normal electric working condition with or without subsequent reconnection ; integrated protection responsive to difference between voltages or between currents; responsive to phase angle between voltages or between currents involving comparison of the voltage or current values at corresponding points in different conductors of a single system, e.g. of currents in go and return conductors using summation current transformers

Landscapes

Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Physics & Mathematics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
General Physics & Mathematics (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Immunology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Analytical Chemistry (AREA)
Biophysics (AREA)
Power Engineering (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Heart & Thoracic Surgery (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Nanotechnology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT06817236T 2005-10-24 2006-10-20 Processos melhorados de focalização PT1948816E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US72923505P	2005-10-24	2005-10-24

Publications (1)

Publication Number	Publication Date
PT1948816E true PT1948816E (pt)	2012-03-19

Family

ID=37968413

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT06817236T PT1948816E (pt)	2005-10-24	2006-10-20	Processos melhorados de focalização

Country Status (11)

Country	Link
US (4)	US9360526B2 (de)
EP (2)	EP2428579B1 (de)
AT (1)	ATE536420T1 (de)
CY (1)	CY1112525T1 (de)
DK (1)	DK1948816T3 (de)
ES (2)	ES2426031T3 (de)
HK (1)	HK1121193A1 (de)
PL (1)	PL1948816T3 (de)
PT (1)	PT1948816E (de)
SI (1)	SI1948816T1 (de)
WO (1)	WO2007050465A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7968287B2 (en)	2004-10-08	2011-06-28	Medical Research Council Harvard University	In vitro evolution in microfluidic systems
EP1712639B1 (de)	2005-04-06	2008-08-27	Maurice Stroun	Methode zur Krebsdiagnose mittels Nachweis von DNA und RNA im Kreislauf
ATE536420T1 (de) *	2005-10-24	2011-12-15	Univ Johns Hopkins	Verbesserte verfahren für beaming
EP3913375A1 (de)	2006-01-11	2021-11-24	Bio-Rad Laboratories, Inc.	Mikrofluidische vorrichtungen und verfahren zur verwendung bei der bildung und steuerung von nanoreaktoren
EP2530167A1 (de)	2006-05-11	2012-12-05	Raindance Technologies, Inc.	Mikrofluidische Vorrichtungen
US9562837B2 (en)	2006-05-11	2017-02-07	Raindance Technologies, Inc.	Systems for handling microfludic droplets
US8772046B2 (en)	2007-02-06	2014-07-08	Brandeis University	Manipulation of fluids and reactions in microfluidic systems
US8592221B2 (en)	2007-04-19	2013-11-26	Brandeis University	Manipulation of fluids, fluid components and reactions in microfluidic systems
GB2453173A (en) *	2007-09-28	2009-04-01	Dxs Ltd	Polynucleotide primers
EP2315629B1 (de)	2008-07-18	2021-12-15	Bio-Rad Laboratories, Inc.	Tröpfchenbibliotheken
US12038438B2 (en)	2008-07-18	2024-07-16	Bio-Rad Laboratories, Inc.	Enzyme quantification
US20100041048A1 (en)	2008-07-31	2010-02-18	The Johns Hopkins University	Circulating Mutant DNA to Assess Tumor Dynamics
US8583380B2 (en)	2008-09-05	2013-11-12	Aueon, Inc.	Methods for stratifying and annotating cancer drug treatment options
EP4484577A3 (de)	2010-02-12	2025-03-26	Bio-Rad Laboratories, Inc.	Digitale analytanalyse
US9399797B2 (en)	2010-02-12	2016-07-26	Raindance Technologies, Inc.	Digital analyte analysis
CA2810931C (en)	2010-09-24	2018-04-17	The Board Of Trustees Of The Leland Stanford Junior University	Direct capture, amplification and sequencing of target dna using immobilized primers
EP3859011A1 (de)	2011-02-11	2021-08-04	Bio-Rad Laboratories, Inc.	Verfahren zur bildung gemischter tröpfchen
EP3736281A1 (de)	2011-02-18	2020-11-11	Bio-Rad Laboratories, Inc.	Zusammensetzungen und verfahren für molekulare etikettierung
DE202012013668U1 (de)	2011-06-02	2019-04-18	Raindance Technologies, Inc.	Enzymquantifizierung
US8658430B2 (en)	2011-07-20	2014-02-25	Raindance Technologies, Inc.	Manipulating droplet size
EP2788500A1 (de) *	2011-12-09	2014-10-15	F.Hoffmann-La Roche Ag	Identifizierung von non-respondern auf her2-inhibitoren
US20130309667A1 (en) *	2012-05-15	2013-11-21	Anthony P. Shuber	Primers for analyzing methylated sequences and methods of use thereof
US10119134B2 (en)	2013-03-15	2018-11-06	Abvitro Llc	Single cell bar-coding for antibody discovery
DE102013211113A1 (de) *	2013-06-14	2014-12-18	Siemens Aktiengesellschaft	Verfahren zur kombinierten Quantifizierung und Sequenzierung von mindestens einer Ziel-Nukleinsäure
US11901041B2 (en)	2013-10-04	2024-02-13	Bio-Rad Laboratories, Inc.	Digital analysis of nucleic acid modification
US9944977B2 (en)	2013-12-12	2018-04-17	Raindance Technologies, Inc.	Distinguishing rare variations in a nucleic acid sequence from a sample
ES2895750T3 (es)	2014-09-15	2022-02-22	Abvitro Llc	Secuenciación de alto rendimiento de colecciones de nucleótidos
CN107427823B (zh) *	2015-03-24	2020-07-14	日立金属株式会社	陶瓷蜂窝结构体
WO2016170179A1 (en) *	2015-04-24	2016-10-27	Qiagen Gmbh	Method for immobilizing a nucleic acid molecule on solid support
US11085073B2 (en)	2015-04-24	2021-08-10	Qiagen Gmbh	Method for immobilizing a nucleic acid molecule on a solid support
US9938572B1 (en)	2015-09-08	2018-04-10	Raindance Technologies, Inc.	System and method for forming an emulsion
CN106929598B (zh) *	2017-05-04	2019-07-05	湖南融健基因生物科技有限公司	一种乳液中进行滚环扩增的数字核酸分析方法
US11701391B2 (en)	2017-10-24	2023-07-18	Dalia ELANI	Methods of treating an ischemic disease
EP3853373A4 (de)	2018-09-17	2022-06-22	The University of North Carolina at Chapel Hill	Verfahren zur quantifizierung von dns-fragmenten in einer probe nach grösse
US11474109B2 (en)	2018-11-16	2022-10-18	Scintimetrics, Inc.	Compositions and methods for controllably merging emulsion droplets and sample analysis
EP3725894A1 (de)	2019-04-16	2020-10-21	Blod Diagnostik GmbH	Vorrichtung und verfahren zur nukleinsäurezielanreicherung, -suspension und -quantifizierung
CN114902024A (zh) *	2019-11-15	2022-08-12	闪璨迈璀公司	基于荧光团扩散的组合物和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5888778A (en) *	1997-06-16	1999-03-30	Exact Laboratories, Inc.	High-throughput screening method for identification of genetic mutations or disease-causing microorganisms using segmented primers
GB9900298D0 (en) *	1999-01-07	1999-02-24	Medical Res Council	Optical sorting method
US6355431B1 (en) *	1999-04-20	2002-03-12	Illumina, Inc.	Detection of nucleic acid amplification reactions using bead arrays
DE10048797A1 (de) *	2000-10-02	2002-04-18	Bayer Ag	Wirkstoffhaltige Emulsionen
AUPS298102A0 (en)	2002-06-13	2002-07-04	Nucleics Pty Ltd	Method for performing chemical reactions
ES2380893T3 (es) *	2003-01-29	2012-05-21	454 Life Sciences Corporation	Amplificación de ácidos nucleicos en emulsión en perlas
EP2918595B1 (de) *	2003-07-05	2019-12-11	The Johns-Hopkins University	Verfahren und Zusammensetzungen zur Detektion und Zählung von genetischen Variationen
WO2005073410A2 (en) *	2004-01-28	2005-08-11	454 Corporation	Nucleic acid amplification with continuous flow emulsion
CA2566538C (en) *	2004-05-13	2023-03-14	Anita Goel	Nano-pcr: methods and devices for nucleic acid amplification and detection
US20060228721A1 (en) *	2005-04-12	2006-10-12	Leamon John H	Methods for determining sequence variants using ultra-deep sequencing
ATE536420T1 (de)	2005-10-24	2011-12-15	Univ Johns Hopkins	Verbesserte verfahren für beaming
US20080242560A1 (en) *	2006-11-21	2008-10-02	Gunderson Kevin L	Methods for generating amplified nucleic acid arrays

2006
- 2006-10-20 AT AT06817236T patent/ATE536420T1/de active
- 2006-10-20 SI SI200631283T patent/SI1948816T1/sl unknown
- 2006-10-20 EP EP11191989.0A patent/EP2428579B1/de not_active Not-in-force
- 2006-10-20 PL PL06817236T patent/PL1948816T3/pl unknown
- 2006-10-20 ES ES11191989T patent/ES2426031T3/es active Active
- 2006-10-20 DK DK06817236.0T patent/DK1948816T3/da active
- 2006-10-20 PT PT06817236T patent/PT1948816E/pt unknown
- 2006-10-20 US US12/091,395 patent/US9360526B2/en active Active
- 2006-10-20 EP EP06817236A patent/EP1948816B1/de not_active Not-in-force
- 2006-10-20 ES ES06817236T patent/ES2381204T3/es active Active
- 2006-10-20 WO PCT/US2006/041115 patent/WO2007050465A2/en active Application Filing
- 2006-10-24 US US12/091,405 patent/US20120014879A1/en not_active Abandoned
2009
- 2009-01-30 HK HK09100870.6A patent/HK1121193A1/xx not_active IP Right Cessation
2012
- 2012-03-07 CY CY20121100229T patent/CY1112525T1/el unknown
2016
- 2016-06-06 US US15/174,427 patent/US10150991B2/en active Active
2018
- 2018-11-08 US US16/184,338 patent/US10837050B2/en active Active

Also Published As

Publication number	Publication date
SI1948816T1 (sl)	2012-04-30
ES2426031T3 (es)	2013-10-18
WO2007050465A2 (en)	2007-05-03
DK1948816T3 (da)	2012-04-02
WO2007050465A3 (en)	2007-10-25
EP1948816A4 (de)	2009-11-04
US20110059435A1 (en)	2011-03-10
ES2381204T3 (es)	2012-05-24
EP2428579B1 (de)	2013-05-29
US20130040300A9 (en)	2013-02-14
EP2428579A1 (de)	2012-03-14
US20200123600A1 (en)	2020-04-23
CY1112525T1 (el)	2015-12-09
US10150991B2 (en)	2018-12-11
US10837050B2 (en)	2020-11-17
ATE536420T1 (de)	2011-12-15
US20160376645A1 (en)	2016-12-29
EP1948816B1 (de)	2011-12-07
HK1121193A1 (en)	2009-04-17
EP1948816A2 (de)	2008-07-30
US9360526B2 (en)	2016-06-07
US20120014879A1 (en)	2012-01-19
PL1948816T3 (pl)	2012-07-31

Publication	Publication Date	Title
US10837050B2 (en)	2020-11-17	Methods for beaming
JP6544861B2 (ja)	2019-07-17	高い選択性の核酸増幅プライマー
BR112013028296B1 (pt)	2020-03-24	Métodos para detecção de variantes de sequências de ácido nucléico
JP6169603B2 (ja)	2017-07-26	単一分子のハイブリダイゼーションおよび操作によるｄｎａの検出および定量法
JP3844996B2 (ja)	2006-11-15	反復性ｐｃｒ産物の融解曲線解析方法
KR102129506B1 (ko)	2020-07-06	핵산 에세이에서의 향상된 용융 식별 및 복합화를 위한 프로브
JP2019536474A (ja)	2019-12-19	メチル化ｄｎａの多重検出方法
US6573047B1 (en)	2003-06-03	Detection of nucleotide sequence variation through fluorescence resonance energy transfer label generation
US9512477B2 (en)	2016-12-06	Biomarker anaylsis using scodaphoresis
Wang et al.	2017	Sensitive detection of cancer gene based on a nicking-mediated RCA of circular DNA nanomachine
EP3775274B1 (de)	2023-12-20	Verfahren zum nachweis von somatischen genetischen anomalien, kombination von fangsonden und nachweiskit
Zhang et al.	2023	CASMART, a one-step CRISPR Cas12a-mediated isothermal amplification for rapid and high-resolution digital detection of rare mutant alleles
Wu et al.	2023	GlaI cleavage assistant isothermal exponential amplification coupling with CRISPR/Cas12a for ultrasensitive detection of CLDN11 methylation: A potential marker for lung adenocarcinoma
EP3553181A1 (de)	2019-10-16	Nukleinsäureamplifikation und anwendung davon
Xiong et al.	2024	Recent advances in enzyme-free and enzyme-mediated single-nucleotide variation assay in vitro
TW202328459A (zh)	2023-07-16	一種腫瘤檢測方法及應用
JP5813263B1 (ja)	2015-11-17	遺伝子変異の検出方法及びそれに用いる蛍光標識オリゴヌクレオチド
US20200216881A1 (en)	2020-07-09	Compositions and methods for detection of genomic variations
Ming et al.	2019	Eliminating the secondary structure of targeting strands for enhancement of DNA probe based low-abundance point mutation detection
JP4359497B2 (ja)	2009-11-04	核酸増幅用プライマー、核酸増幅用プライマーセット及びこれを用いた癌の検査方法
JP2023549569A (ja)	2023-11-27	希少変異の高感度検出のための組成物および方法
JP2024034434A (ja)	2024-03-13	高感度かつ定量的な遺伝子検査方法
Kostas	2017	Optical diagnostics: Nanosensors for liquid biopsies